WO2010076361A1 - Cuerpos de inclusión, células bacterianas y composiciones que los contienen y sus usos - Google Patents
Cuerpos de inclusión, células bacterianas y composiciones que los contienen y sus usos Download PDFInfo
- Publication number
- WO2010076361A1 WO2010076361A1 PCT/ES2009/070616 ES2009070616W WO2010076361A1 WO 2010076361 A1 WO2010076361 A1 WO 2010076361A1 ES 2009070616 W ES2009070616 W ES 2009070616W WO 2010076361 A1 WO2010076361 A1 WO 2010076361A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inclusion body
- ibs
- body according
- cell
- isolated
- Prior art date
Links
- 210000003000 inclusion body Anatomy 0.000 title claims abstract description 133
- 210000004027 cell Anatomy 0.000 title claims abstract description 48
- 230000001580 bacterial effect Effects 0.000 title claims abstract description 30
- 239000000203 mixture Substances 0.000 title claims abstract description 16
- 230000004663 cell proliferation Effects 0.000 claims abstract description 16
- 229920001184 polypeptide Polymers 0.000 claims abstract description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 8
- 210000003527 eukaryotic cell Anatomy 0.000 claims abstract description 8
- 241001465754 Metazoa Species 0.000 claims abstract description 4
- 239000002245 particle Substances 0.000 claims description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 239000000758 substrate Substances 0.000 claims description 13
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 12
- 229910052710 silicon Inorganic materials 0.000 claims description 12
- 239000010703 silicon Substances 0.000 claims description 12
- 241000588724 Escherichia coli Species 0.000 claims description 7
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- 108010067390 Viral Proteins Proteins 0.000 claims description 5
- 102000034287 fluorescent proteins Human genes 0.000 claims description 4
- 108091006047 fluorescent proteins Proteins 0.000 claims description 4
- 108090000565 Capsid Proteins Proteins 0.000 claims description 3
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 3
- 241000588722 Escherichia Species 0.000 claims description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 18
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 18
- 239000005090 green fluorescent protein Substances 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 239000002105 nanoparticle Substances 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000004793 Polystyrene Substances 0.000 description 7
- 230000010261 cell growth Effects 0.000 description 7
- 230000002950 deficient Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 229920002223 polystyrene Polymers 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000004630 atomic force microscopy Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000004626 scanning electron microscopy Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 101000599573 Homo sapiens InaD-like protein Proteins 0.000 description 5
- 102100037978 InaD-like protein Human genes 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 238000002296 dynamic light scattering Methods 0.000 description 5
- 230000005284 excitation Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 108010031318 Vitronectin Proteins 0.000 description 4
- 102100035140 Vitronectin Human genes 0.000 description 4
- 238000004624 confocal microscopy Methods 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 description 4
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 238000004987 plasma desorption mass spectroscopy Methods 0.000 description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108010006519 Molecular Chaperones Proteins 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Substances [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000000942 confocal micrograph Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 2
- BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 102000005431 Molecular Chaperones Human genes 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 239000000560 biocompatible material Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 229910018089 Al Ka Inorganic materials 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 241000252506 Characiformes Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108010003989 D-amino-acid oxidase Proteins 0.000 description 1
- 102000004674 D-amino-acid oxidase Human genes 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 101001078093 Homo sapiens Reticulocalbin-1 Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- CVRXLMUYFMERMJ-UHFFFAOYSA-N N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine Chemical compound C=1C=CC=NC=1CN(CC=1N=CC=CC=1)CCN(CC=1N=CC=CC=1)CC1=CC=CC=N1 CVRXLMUYFMERMJ-UHFFFAOYSA-N 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 102000048245 N-acetylneuraminate lyases Human genes 0.000 description 1
- 108700023220 N-acetylneuraminate lyases Proteins 0.000 description 1
- 101150071459 NAXE gene Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102100025335 Reticulocalbin-1 Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 102000008063 Small Heat-Shock Proteins Human genes 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 238000000026 X-ray photoelectron spectrum Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- -1 argon ion Chemical class 0.000 description 1
- 238000000089 atomic force micrograph Methods 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 101150093586 clpA gene Proteins 0.000 description 1
- 101150074451 clpP gene Proteins 0.000 description 1
- 101150043719 clpP1 gene Proteins 0.000 description 1
- 101150102296 clpP2 gene Proteins 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 238000004320 controlled atmosphere Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 150000002597 lactoses Chemical class 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001459 lithography Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 108010085781 maltodextrin phosphorylase Proteins 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 238000000813 microcontact printing Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- PHQOGHDTIVQXHL-UHFFFAOYSA-N n'-(3-trimethoxysilylpropyl)ethane-1,2-diamine Chemical compound CO[Si](OC)(OC)CCCNCCN PHQOGHDTIVQXHL-UHFFFAOYSA-N 0.000 description 1
- 239000011234 nano-particulate material Substances 0.000 description 1
- 229910052754 neon Inorganic materials 0.000 description 1
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
- 229910001000 nickel titanium Inorganic materials 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 108020000161 polyphosphate kinase Proteins 0.000 description 1
- 230000035409 positive regulation of cell proliferation Effects 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 101150015201 rbsR gene Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 108091052270 small heat shock protein (HSP20) family Proteins 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008646 thermal stress Effects 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Definitions
- the present invention relates to inclusion bodies, bacterial cells and compositions containing them and their use as medicaments and cell proliferation stimulators and tissue regenerators.
- IBs Bacterial inclusion bodies
- IBs Bacterial inclusion bodies
- They are deposits of highly pure proteins produced in recombinant bacteria 1 . Being insoluble in water, they are observed as porous and highly hydrated amorphous particles in the size range of several hundred nanometers.
- the polypeptide chains that form the IBs are folded into an amyloid-like molecular structure compatible with their native structure, thereby maintaining the biological activities of the included polypeptides (eg, fluorescence or enzymatic activity). Therefore, after their proper handling, a wide spectrum of potential uses of IBs as functional and biocompatible materials arises. Although theoretically feasible by adjusting genetic and production conditions, the biophysical characteristics of these proteinaceous particles, such as activity and size, have never been manipulated.
- IBs nanoscale properties of IBs are characterized as new particulate materials and the extent to which the particles produced can be designed using simple strategies is explored.
- modified surfaces have been obtained with inclusion bodies that stimulate Significantly proliferating mammalian cells, demonstrating the potential of IBs in tissue manipulation and regenerative medicine among other promising biomedical applications.
- Many recombinant polypeptides produced in genetically modified bacteria aggregate as IBs. These protein deposits appear as highly hydrated particles found in bacterial cytoplasm 2 or, in some cases, in periplasm 3 .
- the IBs are chemically pure, since the recombinant protein itself is the main component - to about 95% of the total protein - 2 '4' 5.
- IBs RNA, DNA and lipids are trapped during the formation of IB and are present in smaller amounts 6 .
- the formation of IBs is a fast and efficient process, as observed after a few minutes of induction of gene expression. Several hours later, they can easily represent around 50% of the total cell biomass 5 .
- IBs were formed by unfolded or widely misfolded polypeptide chains and, therefore, biologically inert, recent observations, they present these particles as constituted by protein species that fold correctly and, therefore, , are biofunctional 8 .
- the molecular structure of IBs is based on a particular organization of amyloid - 9 '10 which allows cross - beta sheet interactions with coexisting domains correctly folded proteins 11.
- enzyme-formed IBs can be useful catalysts in different types of bioprocesses as recently observed for ⁇ -galactosidase, D-amino acid oxidase, maltodextrin phosphorylase, sialic acid aldolase and polyphosphate kinase 11 15 , among others.
- its in vivo formation which involves the deposition of proteins dependent on the sequence around nucleation centers, it is regulated by several cellular genes (which mainly encode proteases and chaperones that act as a functional network, which allows the manipulation of their nanoscale properties) 16 '".
- IBs determine the most relevant characteristics of IB as nanoparticles and test that can be designed by genetic manipulation and the appropriate process of the producing bacteria.As they are fully biocompatible and mechanically stable materials, IBs have also been used as nanoparticles to modify the roughness of the surfaces for the stimulation of mammalian cell proliferation Since essentially any species of protein can be produced as bacterial IBs and their nanoscale properties can be easily adjusted, the functional possibilities of these novel materials offer an unusual spectrum of biomedical applications Additional ics apart from those shown here in the context of tissue manipulation.
- the present invention relates to inclusion bodies, bacterial cells and compositions containing them and their use as cell proliferation stimulators and tissue regenerators.
- a first object of the present invention relates to an isolated inclusion body comprising a polypeptide characterized in that the inclusion body is in particulate form.
- a second object of the present invention relates to a bacterial cell comprising the inclusion body according to the first object of the invention and its different structural aspects.
- a third object of the present invention relates to a composition comprising the inclusion body according to the first object of the invention and its different structural aspects and a eukaryotic cell.
- a fourth object of the present invention relates to a composition comprising the inclusion body according to the first object of the invention and its different structural aspects and an animal or plant tissue.
- a fifth object of the present invention relates to the uses of the inclusion body according to the first object of the invention and its different structural and dispositional aspects, such as medicaments and cell proliferation stimulators and tissue regenerators.
- FIG. 1 Morphological and functional characterization of IBs.
- A Confocal microscopy images of wild bacterial cells that produce IBs formed by a GFP fusion protein. From top to bottom, cell samples taken at 1 hour, 2 hours and 3 hours after induction of IB production.
- B Images of confocal microscopy using a Metamorf palette of wild bacterial cells, IbpAB, CIpA, CIpP and DnaK that produce IBs formed by a fusion GFP of 2 hours of formation (upper part). Confocal microscopy images of purified 3-hour IBs of these strains (lower part). The bars in A and B indicate 1 ⁇ m.
- C Confocal microscopy images of wild bacterial cells that produce IBs formed by a GFP fusion protein. From top to bottom, cell samples taken at 1 hour, 2 hours and 3 hours after induction of IB production.
- B Images of confocal microscopy using a Metamorf palette of wild bacterial cells, Ib
- D the growth of BHK cells at different incubation times on plates coated with IB (IB), on plates coated with vitronectin (V) and on control plates (C).
- E Growth of BHK cells in plates coated with different concentrations of IBs compared to vitronectin-coated plates (V) and control plates (C). The experiments were carried out in parallel on polystyrene plates treated for culture (black bars) and untreated (gray bars).
- G Images of the amino-terminated silicon surfaces stamped with 50 ⁇ m coated IBs taken by conventional microscopy (upper part) and confocal microscopy (middle part) and the distribution of BHK cells after 48 hours of growth on them (part lower) .
- inclusion body or also referred to in the present invention as “IB” is understood as indicated above in the background section or, more simply, an intracellular amorphous deposit comprising aggregate proteins found in the cytoplasm of a cell.
- a first object of the present invention relates to an isolated inclusion body comprising a polypeptide characterized in that the inclusion body is in particulate form.
- the particulate form has a particle size between 24 and 1500 nm. In a more preferred embodiment, the particle is in hydrated amorphous form.
- this may be a chimeric polypeptide comprising a viral protein fused translationally with a reporter protein.
- said viral protein is a capsid protein.
- the reporter protein is a fluorescent protein.
- said fluorescent protein is GFP (green fluorescent protein).
- the inclusion body according to the first object of the invention and its different structural aspects is deposited on a plate treated with tissue culture.
- the inclusion body according to the first object of the invention and its different structural aspects is deposited on a silicon substrate.
- the inclusion body according to the first object of the invention and its different structural aspects is incorporated into a three-dimensional scaffolding, whether synthetic or natural.
- a second object of the present invention relates to a bacterial cell comprising the inclusion body according to the first object of the invention and its different structural aspects.
- said bacterial cell is Escherichia CoIi (E. coli).
- said E. coli bacterial cell is a wild strain (WT) or is a mutant strain.
- a third object of the present invention relates to a composition comprising the inclusion body according to the first object of the invention and its different structural aspects and a eukaryotic cell.
- said eukaryotic cell is a mammalian cell.
- a fourth object of the present invention relates to a composition
- a composition comprising the inclusion body according to the first object of the invention and its different structural aspects and an animal or plant tissue.
- a fifth object of the present invention relates to the uses of the inclusion body according to the first object of the invention and its different structural and layout aspects.
- a first use of said inclusion body is as a stimulator of eukaryotic cell proliferation.
- a second use of said inclusion body is as a tissue regenerator.
- a third use of said inclusion body is as medicine.
- such use as a medicine would take into account the observed advantages (see experimental part) in cell proliferation and tissue regeneration.
- IBs were produced in different strains of Escherichia coli, specifically MC4100 (wild strain with respect to protein folding and degradation, araD139 A (argF-lac) U169 rpsLl50 relAl flbB5301 deoCl ptsF25 rbsR) 1S and its derivatives JGT4 (deficient in co - CIpA protease, clpA :: kan), JGT17 (deficient in small heat shock proteins IbpAB, Aibp:: kan), JGT19 (deficient in co-protease CIpP, clpP:: cat) and JGT20 (deficient in chaperone main DnaK, dnak756 thr :: TnIO) 19 .
- MC4100 wild strain with respect to protein folding and degradation
- araD139 A argF-lac
- JGT17 deficient in small heat shock proteins IbpAB, Aibp::
- Nonidet P40 NP-40
- the DNA was extracted with 120 ⁇ l of 1 mg / ml DNase and 120 ⁇ l of 1 M Mg 2 SO 4 for 45 minutes at 37 ° C with stirring.
- the samples were centrifuged at 4 ° C at 15000 g for 15 minutes and the residue, which contained pure IBs, was washed with lysis buffer containing 0.5% Triton X-100 and stored at -20 ° C Until your analysis.
- the purified IBs were resuspended in PBS and sonicated for 4 minutes under 0.5 s cycles and analyzed by flow cytometry in a FACS Calibur (Becton Dickinson) system, using an 15 mW air cooled argon ion laser at excitation of a wavelength of 488 nm.
- the fluorescence emission of IB was measured in the FL-I channel (530/30 nm bandpass filter) using a logarithmic mode.
- Atomic force microscopy (AFM) analysis was performed in air with a commercial atomic force microscope (PicoScan / PicoSPM of Molecular Imaging
- volume size distributions of IB and Z potential were measured using a dynamic light scattering analyzer (DLS) at a wavelength of 633 nm, combined with a non-invasive backscattering technology (NIBS) (Zetasizer Nano ZS , Malvern Instruments Limited, Malvern, United Kingdom).
- Silicon substrates (100) 1x1 cm polished on one side were used for the preparation of amino-terminated monolayers. Prior to the formation of the monolayer, the substrates were treated with oxidizing RCAl solution (NH 4 OH / H 2 O 2 / H 2 O in a 1: 1: 5 ratio) for 30 minutes at 80 ° C and rinsed so Light with ultrapure water / MilliQ with a conductivity greater than 18.2 M ⁇ . Subsequently, the substrates were introduced in piranha solution for 15 minutes (concentrated H 2 SO 4 (Panreac) and 33% aqueous H 2 O 2 (Aldrich) in a 3: 1 ratio), rinsed thoroughly with ultrapure water and dried under a stream of nitrogen.
- oxidizing RCAl solution NH 4 OH / H 2 O 2 / H 2 O in a 1: 1: 5 ratio
- This treatment provides the substrates with a new hydroxyl-terminated surface for subsequent reactions.
- the amino-terminated monolayers were formed by exposure of the substrates under controlled atmosphere to a 5 mM solution of N- [3- (trimethoxysilyl) propyl] ethylenediamine / (TPEDA) (97% Aldrich) in anhydrous toluene for 3 hours. After the formation of the monolayer, the substrates were rinsed with toluene and ethanol to remove excess silane and dried under a stream of nitrogen.
- the contact angle of the amino-terminated substrate was measured with a drop of 3 ⁇ l of ultrapure water (MiIIiQ with 18.2 M ⁇ cm) in a 0CA15 + Contact Angle Measurement Instrument (Data Physics Instruments GMBH, Germany), equipped with a CCD camera and the SCA20 software for angle determination.
- the XPS spectra were obtained on a PHI ESCA-500 instrument (Perkin Elmer), equipped with a monochromatic Al Ka X-ray source operating at 350 W. The spectra referred to the main IC peak observed at 284.8 eV.
- the ⁇ CP of IBs on the amino-terminated silicon substrate was performed using PDMS stamping (Sylgard 184, Dow Corning, United States).
- the prints were manufactured by casting a 10: 1 (v / v) mixture of PDMS and curing agent (Sylgard 184, Dow Corning) against a silicon base with a photolithographic pattern, cured for 1 hour at 60 ° C and extracted at this cure temperature.
- PDMS prints were left in the oven at 60 ° C for at least 18 hours to ensure complete cure.
- PDMS prints were impregnated with a PBS buffer suspension with IB (pH 7.5) for 40 minutes, dried under a stream of nitrogen and placed on a clean substrate surface of finished silicon in amino. After a contact time of 1 minute was stamped with caution.
- the fluorescence of the printed samples was analyzed using a Leica TSC SPE confocal fluorescence microscope (Leica Microsystems Heidelberg GMBH, Manheim, Germany) after an excitation at a wavelength of 488 nm and recovered at an emission between 500 and 600 nm (x 10 air).
- IBs formed in DNak cells for 5 hours were diluted in PBS with bovine serum albumin (BSA) 10 g / 1 and sucrose 60 g / 1, in the presence of gentamicin 40 mg / 1, penicillin 100 U / ml and streptomycin 10 ⁇ g / ml, and aliquots were incubated at different temperatures (37 ° C, 25 ° C or 4 ° C). At different times, samples were frozen at -80 ° C until fluorescence determination. Fluorescence was recorded at 510 nm on a Cary Eclipse fluorescence spectrophotometer (Variant, Inc., Palo Alto, CA) using an excitation wavelength of 450 nm.
- BSA bovine serum albumin
- results are referred to as the percentage of activity or fluorescence remaining with respect to control samples maintained at -80 ° C that were completely stable.
- Another group of samples were lyophilized in a Cryodos-80 lyophilizer, from Telstar, and stored at 4 ° C or 25 ° C until analysis.
- the inclusion bodies with isolated GFPs as described above were sterilized after 3 hours of production under exposure to a 253 nm UV light germicidal lamp for 4 hours. They were then resuspended in PBS and used.
- different amounts of IB protein specifically 0.08, 0.8 and 8 ⁇ g per well to coat 96-well Falcon 3072 polystyrene plates treated with tissue culture (Becton Dickinson) or untreated Costar 3370 plates, overnight 4 ° C Vitronectin (Calbiochem) was used as a reference at a concentration of 50 ng / cm 2 , following the manufacturer's instructions.
- the wells were washed in PBS and blocked with 3% BSA in PBS for 1 hour at 37 ° C.
- DMEM Dulbecco's Modified Eagle Medium
- cell proliferation was determined using the EZ4U kit (Biomedica, GMBH) following the manufacturer's instructions and analyzed in the V ⁇ CTOR 3 V 1420 multibrand reader (Perkin Elmer). The reading absorbances were 450 nm and 620 nm as a reference and the values obtained were standardized with respect to the wells containing only medium. A pre-test was carried out to select the incubation time before saturation with the kit reagents; The optimal times were 3 hours for 24-hour crops, 2 hours for 48-hour crops and 30 minutes for 72-hour crops. All trials were performed in triplicate.
- the cells were incubated with 5 ⁇ g / ml of Hoechst 33342 and 5 ⁇ g / ml of CellMask (both of Molecular Probes, Inc., Eugene, OR, United States), respectively, for 5 minutes at room temperature and washed twice before confocal detection.
- the Z series of 22 optical sections were collected in a range of 0.6 ⁇ m.
- the Z layers were obtained with LAS AF software (Leica Microsystems) and three-dimensional models were generated using the Imaris software (Bitplane, Zürich, Switzerland). Results and Discussion
- IBs formed by green fluorescent protein (GFP) are very convenient models for a kinetic and functional analysis of their biological production, since they are highly fluorescent 20 .
- GFP green fluorescent protein
- the appropriate combination between the collection time during the production process (which determines the stage of growth of IB) and the producing strain (which determines both the biological activity and the upper size limit) define the specific particle and fluorescence dimensions that could be more suitable for different applications.
- the IBs obtained in CIpA and CIpP cells, with a very similar particle size (0.435 and 0.459 nm, respectively) showed different levels of fluorescence emission (71 and 184 average FLl units per particle, respectively).
- the mapping of the fluorescence of IBs with GFP was comparable in all strains, showing a common homogeneous central fluorescent pattern (Figure IB).
- silica and ceramic nanoparticles between 24 and 1500 nm in diameter affect cell growth functions and can positively modulate cell proliferation on decorated surfaces 24 '26 . Since we question whether bacterial IBs that appear in this size range could also be useful for surface nanomanipulation, the effect of IBs with GFP was tested, once deposited in polystyrene plates treated with tissue culture (Figure 3A) , at BHK21 cell growth ( Figure 3B, C). At a density of 0.05 particles / ⁇ m 2 , the IBs showed a mean square root roughness (RMS) of 55.9 nm.
- RMS mean square root roughness
- FIG. 3G shows the surface of silicon stamped with IBs at a density of 0.04 Ibs / ⁇ m 2 and an RMS roughness of 32.4 nm, as well as the consequent stimulation of cell proliferation in regions linearly decorated with IBs. This indicates the preference for cell growth induced by IBs and the ability of these nanoparticles to stimulate cell proliferation on surfaces initially not suitable for cell growth.
- IBs produced in bacteria can be precisely designed during biological production with respect to important nanoscale-level characteristics and are intriguing nanoparticulate materials produced through economic processes by biological systems. Being biofunctional by nature and given that the protein that forms them can be selected and that their biological activity can be modulated by the genetic modification of the producer cell, the manipulation of IBs could have wide and deep implications in different nanomedical fields. In particular, and as the first proof of concept of biomedical applicability, IBs effectively functionalize surfaces thereby significantly favoring the proliferation of bound mammalian cells.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2749067A CA2749067A1 (en) | 2008-12-30 | 2009-12-22 | Inclusion bodies, bacterial cells and compositions containing them and their uses |
US13/142,295 US20110268773A1 (en) | 2008-12-30 | 2009-12-22 | Inclusion bodies, bacterial cells and compositions containing them and uses thereof |
EP09836114A EP2377946A4 (en) | 2008-12-30 | 2009-12-22 | INCLUSION BODY, BACTERIAL CELLS AND COMPOSITIONS CONTAINING SAME, AND USES THEREOF |
JP2011544063A JP2012514025A (ja) | 2008-12-30 | 2009-12-22 | 封入体、これを含有する細菌細胞および組成物、ならびにこれらの使用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200900045A ES2352489B1 (es) | 2008-12-30 | 2008-12-30 | Cuerpos de inclusión, celulas bacterianas y composiciones que los contienen y sus usos. |
ESP200900045 | 2008-12-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010076361A1 true WO2010076361A1 (es) | 2010-07-08 |
WO2010076361A8 WO2010076361A8 (es) | 2011-10-20 |
Family
ID=42309867
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2009/070616 WO2010076361A1 (es) | 2008-12-30 | 2009-12-22 | Cuerpos de inclusión, células bacterianas y composiciones que los contienen y sus usos |
Country Status (6)
Country | Link |
---|---|
US (1) | US20110268773A1 (es) |
EP (1) | EP2377946A4 (es) |
JP (1) | JP2012514025A (es) |
CA (1) | CA2749067A1 (es) |
ES (1) | ES2352489B1 (es) |
WO (1) | WO2010076361A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112014013369A2 (pt) | 2011-12-01 | 2017-06-13 | Barofold Inc | métodos e sistemas para redobramento de proteína |
KR20160083884A (ko) | 2013-11-01 | 2016-07-12 | 스페리움 바이오메드 에스.엘. | 치료제 및 미용제의 경피 전달을 위한 봉입체 |
-
2008
- 2008-12-30 ES ES200900045A patent/ES2352489B1/es not_active Expired - Fee Related
-
2009
- 2009-12-22 US US13/142,295 patent/US20110268773A1/en not_active Abandoned
- 2009-12-22 CA CA2749067A patent/CA2749067A1/en not_active Abandoned
- 2009-12-22 EP EP09836114A patent/EP2377946A4/en not_active Withdrawn
- 2009-12-22 WO PCT/ES2009/070616 patent/WO2010076361A1/es active Application Filing
- 2009-12-22 JP JP2011544063A patent/JP2012514025A/ja not_active Withdrawn
Non-Patent Citations (37)
Title |
---|
ANNA M. LIPSKI ET AL.: "The effect of silica nanoparticle-modified surfaces on cell morphology, cytoskeletal organization and function", BIOMATERIALS, vol. 29, 1 October 2008 (2008-10-01), pages 3836 - 3846, XP023611026 * |
ARIE, J. P., MIOT, M., SASSOON, N., BETTON, J. M.: "Formation of active inclusion bodies in the periplasm of Escherichia coli", MOL. MICROBIOL., vol. 62, 2006, pages 427 - 437 |
BANEYX, F., MUJACIC, M.: "Recombinant protein folding and misfolding in Escherichia coli", NAT. BIOTECHNOL., vol. 22, 2004, pages 1399 - 1408 |
BOWDEN, G. A., PAREDES, A. M., GEORGIOU, G.: "Structure and morphology of protein inclusion bodies in Escherichia coli", BIOTECHNOLOGY (N. Y., vol. 9, 1991, pages 725 - 730 |
CARRIO, M. M., CORCHERO, J. L., VILLAVERDE, A: "Dynamics of in vivo protein aggregation: building inclusion bodies in recombinant bacteria", FEMS MICROBIOL LETT, vol. 169, 1998, pages 9 - 15 |
CARRIO, M. M., CUBARSI, R., VILLAVERDE, A: "Fine architecture of bacterial inclusion bodies", FEBS LETT, vol. 471, 2000, pages 7 - 11 |
CARRIO, M. M., VILLAVERDE, A.: "Role of molecular chaperones in inclusion body formation", FEBS LETT, vol. 537, 2003, pages 215 - 221 |
CARRIO, M., GONZALEZ-MONTALBAN, N., VERA, A., VILLAVERDE, A., VENTURA, S.: "Amyloid-like properties of bacterial inclusion bodies", J. MOL. BIOL., vol. 347, 2005, pages 1025 - 1037 |
DAVID D. CHOIE ET AL.: "Cell proliferation in rat kidneys after prolonged treatment with lead", AMERICAN JOURNAL OF PATHOLOGY, vol. 68, no. 2, 1972, pages 359 - 370, XP008142085 * |
DAWN M. YANKER, JOSHUA A. MAUER: "Direct printing of trichlorosilanes on glass for selective protein adsorption and cell growth", MOL. BIOSYST., vol. 4, 2008, pages 502 - 504 |
DOROTA I., ROZKIEWICZ, BART JAN RAVOO, DAVID N.: "Reinhoudt Reversible Covalent Patterning of Self- Assembled Monolayers on Gold and Silicon Oxide Surfaces", LANGMUIR, vol. 21, 2005, pages 6337 - 6343 |
DULGAR-TULLOCH, A. J., BIZIOS, R., SIEGEL, R. W.: "Human mesenchymal stem cell adhesion and proliferation in response to ceramic chemistry and nanoscale topography", J. BIOMED. MATER. RES. A, 2008 |
EL-GHANNAM, A. R. ET AL.: "Model surfaces engineered with nanoscale roughness and RGD tripeptides promote osteoblast activity", J. BIOMED. MATER. RES. A, vol. 68, 2004, pages 615 - 627 |
GARCIA-FRUITOS, E. ET AL.: "Aggregation as bacterial inclusion bodies does not imply inactivation of enzymes and fluorescent proteins", MICROB. CELL FACT., vol. 4, 2005, pages 27 |
GARCIA-FRUITOS, E. ET AL.: "Divergent Genetic Control of Protein Solubility and Conformational Quality in Escherichia coli", J. MOL. BIOL., vol. 374, 2007, pages 195 - 205 |
GARCIA-FRUITOS, E., ARIS, A., VILLAVERDE, A.: "Localization of functional polypeptides in bacterial inclusion bodies", APPL. ENVIRON. MICROBIOL., vol. 73, 2007, pages 289 - 294 |
JEONG HYUN SEO ET AL.: "Baculoviral polyhedrin as a novthe fusion partner for formation of inclusion body in Escherichia coli", BIOTECHNOLOGY AND BIOENGIEEREING, vol. 84, 20 November 2003 (2003-11-20), pages 467 - 473, XP008140776 * |
KANE, R. S., TAKAYAMA, S., OSTUNI, E., INGBER, D. E., WHITESIDES, G. M.: "Patterning proteins and cells using soft lithography", BIOMATERIALS, vol. 20, 1999, pages 2363 - 2376 |
KWANG KOOK LEE ET AL.: "Abnormal cell division caused by inclusion bodies in E. coli; increased resistance against external stress", MICROBIOLOGICAL RESEARCH., vol. 163, 15 July 2008 (2008-07-15), pages 394 - 402, XP022716393 * |
LIPSKI, A. M., PINO, C. J., HASELTON, F. R., CHEN, I. W., SHASTRI, V. P.: "The effect of silica nanoparticle- modified surfaces on cell morphology, cytoskeletal organization and function", BIOMATERIALS, 2008 |
LUDDEN, M. J., MULDER, A., TAMPE, R., REINHOUDT, D. N., HUSKENS, J.: "Molecular printboards as a general platform for protein immobilization: a supramolecular solution to nonspecific adsorption", ANGEW. CHEM. INT. ED ENGL., vol. 46, 2007, pages 4104 - 4107 |
MARGREITER, G., MESSNER, P., CALDWELL, K. D., BAYER, K.: "Size characterization of inclusion bodies by sedimentation field-flow fractionation", J. BIOTECHNOL., vol. 138, 2008, pages 67 - 73 |
MASAKI UCHIDA, MICHAEL T. KLEM, MARK ALLEN, PETER SUCI, MICHELLE FLENNIKEN, ERIC GILLITZER, ZACHARY VARPNESS, LARS O. LIEPOLD, MAR: "Biological Containers: Protein Cages as Multifunctional Nanoplatforms", ADV. MATER., vol. 19, 2007, pages 1025 - 1042 |
NAHALKA, J., DIB, I., NIDETZKY, B.: "Encapsulation of Trigonopsis variabilis D-amino acid oxidase and fast comparison of the operational stabilities of free and immobilized preparations of the enzyme", BIOTECHNOL. BIOENG., vol. 99, 2008, pages 251 - 260 |
NAHALKA, J., GEMEINER, P., BUCKO, M., WANG, P. G.: "Bioenergy beads: a tool for regeneration of ATP/NTP in biocatalytic synthesis", ARTIF. CELLS BLOOD SUBSTIT. IMMOBIL. BIOTECHNOL, vol. 34, 2006, pages 515 - 521 |
NAHALKA, J., VIKARTOVSKA, A., HRABAROVA, E.: "A crosslinked inclusion body process for sialic acid synthesis", J. BIOTECHNOL, vol. 134, 2008, pages 146 - 153 |
NAHALKA, J.: "Physiological aggregation of maltodextrin phosphorylase from Pyrococcus furiosus and its application in a process of batch starch degradation to alpha-D: -glucose-1-phosphate", J. IND. MICROBIOL. BIOTECHNOL., vol. 35, 2008, pages 219 - 223 |
RENAULT, J. P. ET AL.: "Fabricating microarrays of functional proteins using affinity contact printing", ANGEW. CHEM. INT. ED ENGL., vol. 41, 2002, pages 2320 - 2323 |
SAMAROO, H. D., LU, J., WEBSTER, T. J.: "Enhanced endothelial cell density on NiTi surfaces with submicron to nanometer roughness", INT. J. NANOMEDICINE, vol. 3, 2008, pages 75 - 82 |
SAMBROOK, J., FRITSCH, E., MANIATIS, T.: "Molecular Cloning, A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS |
See also references of EP2377946A4 |
SHU-HAN HSU, DAVID N.: "Reinhoudt, Jurrian Huskens, and Aldrik H. Velders, Imidazolide monolayers for reactive microcontact printing", J. MATER. CHEM., vol. 18, 2008, pages 4959 - 4963 |
SUCI, P. A., KLEM, M. T., ARCE, F. T., DOUGLAS, T., YOUNG, M.: "Assembly of multilayer films incorporating a viral protein cage architecture", LANGMUIR, vol. 22, 2006, pages 8891 - 8896 |
THOMAS, J. G., BANEYX, F.: "Roles of the Escherichia coli small heat shock proteins IbpA and IbpB in thermal stress management: comparison with ClpA, ClpB, and HtpG In vivo", J BACTERIOL, vol. 180, 1998, pages 5165 - 5172 |
VENTURA, S., VILLAVERDE, A.: "Protein quality in bacterial inclusion bodies", TRENDS BIOTECHNOL., vol. 24, 2006, pages 179 - 185 |
VILLAVERDE, A., CARRIO, M. M.: "Protein aggregation in recombinant bacteria: biological role of inclusion bodies", BIOTECHNOL LETT, vol. 25, 2003, pages 1385 - 1395 |
WANG, L., MAJI, S. K., SAWAYA, M. R., EISENBERG, D., RIEK, R.: "Bacterial inclusion bodies contain amyloid-like structure", PLOS. BIOL., vol. 6, 2008, pages E195 |
Also Published As
Publication number | Publication date |
---|---|
JP2012514025A (ja) | 2012-06-21 |
EP2377946A4 (en) | 2013-02-06 |
CA2749067A1 (en) | 2010-07-08 |
WO2010076361A8 (es) | 2011-10-20 |
ES2352489B1 (es) | 2012-01-04 |
ES2352489A1 (es) | 2011-02-21 |
EP2377946A1 (en) | 2011-10-19 |
US20110268773A1 (en) | 2011-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ferraz et al. | Surface cell growth engineering assisted by a novel bacterial nanomaterial | |
AU2005226595B2 (en) | Mussel bioadhesive | |
Balasundaram et al. | TiO2 nanotubes functionalized with regions of bone morphogenetic protein‐2 increases osteoblast adhesion | |
Subramani et al. | Self-assembly of proteins and peptides and their applications in bionanotechnology and dentistry | |
Childs et al. | Novel biologically-inspired rosette nanotube PLLA scaffolds for improving human mesenchymal stem cell chondrogenic differentiation | |
US8673845B2 (en) | Carrier peptide fragment and use thereof | |
KR20130087369A (ko) | 양친매성 선형 펩티드/펩토이드 및 이를 포함하는 히드로겔 | |
Zhang et al. | Compatibility of neural stem cells with functionalized self-assembling peptide scaffold in vitro | |
WO2018021543A1 (ja) | 幹細胞の製造に用いられるフィブロネクチンフラグメント | |
CN113396154A (zh) | 自组装短两亲性肽以及相关的方法和用途 | |
Collier | Modular self-assembling biomaterials for directing cellular responses | |
Ghezzi et al. | Hydrogen plasma treatment confers enhanced bioactivity to silicon carbide-based nanowires promoting osteoblast adhesion | |
Yoo et al. | Engineered phage nanofibers induce angiogenesis | |
Öztürk-Öncel et al. | A facile surface modification of poly (dimethylsiloxane) with amino acid conjugated self-assembled monolayers for enhanced osteoblast cell behavior | |
WO2010076361A1 (es) | Cuerpos de inclusión, células bacterianas y composiciones que los contienen y sus usos | |
ES2345500T3 (es) | Uso de celulas madre para inducir la diferenciacion neural. | |
JP6084352B2 (ja) | 高強度ペプチドゲル | |
US9011914B2 (en) | Hetero-assembled hydrogels | |
Takeuchi et al. | Biomimetic deposition of hydroxyapatite on a synthetic polypeptide with β sheet structure in a solution mimicking body fluid | |
WO2003020316A1 (fr) | Matieres a liberation lente de medicament in vivo | |
WO2012168532A1 (es) | Biopolímero termosensible y bioactivo y método de recolección celular asociado | |
KR20160121780A (ko) | 세포와 세포간의 결합 증진을 위한 고분자 지지체 및 이를 이용한 세포 배양 방법 | |
WO2013002311A1 (ja) | 幹細胞培養用基材及びそれを用いた培養方法 | |
Ni | Ultrashort peptides: Minimum number in amino acid residues, maximum number in bioapplications | |
WO2019239751A1 (ja) | 細胞移植用組成物及び細胞移植方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09836114 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2749067 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13142295 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2011544063 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009836114 Country of ref document: EP |